Switching "Real-World" Diabetes Patients to Degludec from Other Basal Insulins Provides Different Clinical Benefits According to Their Baseline Glycemic Control.

ABSTRACT:

Introduction

The stable, ultra-long duration of action of insulin degludec (degludec) minimizes fluctuations in glucose-lowering activity over the daily (24-h) dosing period, and comparative studies with other basal insulins suggest that these properties translate into a lower risk of hypoglycemia at equivalent levels of glycemic control. Results from the real-world European multicenter, retrospective chart review study of 2550 patients with type 1 and type 2 diabetes (T1D and T2D) in routine clinical care EU-TREAT (NCT02662114) showed that patients benefited from improved glycemic control and significantly reduced rates of hypoglycemia following a switch to degludec.

Methods

In this post hoc analysis, EU-TREAT patients were stratified into good (≤ 7.5% HbA1c), intermediate

SUBMITTER: Tentolouris N 

PROVIDER: S-EPMC6824376 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature